Sigma Healthcare stock closed at A$2.62, with the shares drifting over the past month even as the company posted one of the stronger profit stories in Australian healthcare retail this season. The headline is simple: normalised net profit after tax reached A$732 million and normalised earnings per share came in at A$0.064, backed by a A$0.04 full year dividend.
The short term price softness now sits against a business that has lifted earnings faster than revenue and is running a trailing net profit margin of 6.5%. The rest of the numbers help explain that gap between price and progress.
Impressed by Sigma Healthcare lifting earnings faster than revenue, but want to see how it stacks up against peers with similar margins and income profiles? Check out our hand picked screener of list of solid balance sheet and fundamentals stocks (22 results)
FY 2026 Earnings Summary
- Revenue FY 2026: A$10,834.97m vs. A$6,001.84m in FY 2025 trailing twelve months (very large increase)
- Net Income FY 2026 (Excl. Extra Items): A$709.18m vs. A$529.91m in FY 2025 trailing twelve months (up 33.8%)
- Basic EPS FY 2026: A$0.062 vs. A$0.0506 in FY 2025 trailing twelve months (up about 22.6%)
- Net Profit Margin FY 2026: 6.5% vs. 8.8% a year earlier (margin compression)
If you prefer clear visuals instead of scanning rows of earnings figures and margin data, explore Sigma Healthcare's complete financial profile, including a concise view of its profitability trends, in the interactive company report for Sigma Healthcare.
Sigma Healthcare: Earnings Momentum Backs Positive View
Sigma Healthcare gives bulls some support. Revenue and normalised NPAT both move higher, and normalised EPS rises to A$0.064 alongside a A$0.04 full year dividend. Net debt falls to A$663m and net debt to normalised EBITDA sits at about 0.57x, helped by A$500m of free cash flow. Australian and international EBIT both grow faster than their revenue, which points to operating leverage even with some gross margin pressure. For a defensive pharmacy and distribution model, that mix of growth, cash generation and moderate gearing leans in favour of the optimistic narrative.
Margin Pressure, Working Capital And Execution Risks
The cautious view on Sigma Healthcare is not disproved. Net profit margin eases from 8.8% to 6.5%, and management flags GLP 1 medicines as dilutive to gross margin percentage. Inventory rises 22% and the cash conversion cycle stretches to 54 days, which ties up more capital in a low margin model. Integration and synergy delivery require ongoing one off costs and operational focus, while international expansion, including a new UK joint venture, introduces execution and early loss risk. Recent share price weakness over 30 and 90 days shows the market is still weighing these issues.
With net profit margin lower than last year and leverage still relevant for Sigma Healthcare, many investors want to verify the true buffer in cash, debt and covenants. Check the detailed solvency picture in our financial health analysis of Sigma Healthcare stock.Stay Ahead Of Your Next Move
If Sigma Healthcare's mix of earnings growth, cash generation and recent share price softness has your attention, register for free with Simply Wall St and add it to a Watchlist to track price against fair value and watch for an entry point that fits your plan. After you build a position, keep a clear view of Sigma Healthcare alongside your other holdings with the Portfolio Command Center that filters out noise and highlights the most important updates. For a broader view, use the Community to see how other investors are thinking about stocks like Sigma Healthcare and what they are watching next. This way you are set up to monitor potential catalysts and risks early and stay a step ahead of the market.
Seeking Alternatives Beyond Sigma Healthcare?
Fresh stock ideas can move from quiet to flying once momentum builds and early buyers get caught on the right side of a breakout. Look under the radar for now and act now.
- Spot resilient businesses where balance sheets back the story and cash strength still matters by scanning our curated list of solid balance sheet and fundamentals stocks (22 results) before the crowd closes the gap.
- Target consistent income streams while payouts remain elevated and prices have not fully adjusted by reviewing the hand picked set of 8 dividend fortresses built for yield focused investors.
- Ride structural growth themes with companies using AI to reshape healthcare workflows by checking the focused selection of 8 healthcare AI stocks while it still flies under many radars.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com